Evidence map›Paper›PMID 38582089›Full record

ArticleThe Lancet. Infectious diseases2024

Viral shedding and viraemia of Andes virus during acute hantavirus infection: a prospective study.

Marcela Ferrés, Constanza Martínez-Valdebenito, Carolina Henriquez, Claudia Marco, Jenniffer Angulo, Aldo Barrera, Carlos Palma, Gonzalo Barriga Pinto, Analia Cuiza, Leonila Ferreira and 15 more

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in The Lancet. Infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Andes Virus: From Transmission Dynamics to Pandemic Potential.European journal of clinical investigation · 2026
    Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. TheThe Lancet regional health. Europe · 2026
    Article
  14. Article
  15. Article
  16. Article
  17. Human Orthohantavirus Infections: A Narrative Review.Pathogens (Basel, Switzerland) · 2026
    Review
  18. Andes hantavirus - A primer.Npj viruses · 2026
    Article
  19. Review
  20. Why Andes hantavirus is not the next SARS-CoV-2: contrasting viral shedding, transmissibility and genomic patterns.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2026
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors at 10 institutions in 2 countries.

Marcela FerrésDepartamento de Enfermedades Infecciosas e Inmunología Pediátricas, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile; Laboratorio de Infectología y Virología Molecular, Red Salud UC-Christus, Santiago, Chile. Electronic address: mferres@uc.cl.
Constanza Martínez-ValdebenitoDepartamento de Enfermedades Infecciosas e Inmunología Pediátricas, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile; Laboratorio de Infectología y Virología Molecular, Red Salud UC-Christus, Santiago, Chile.
Carolina HenriquezDepartamento de Enfermedades Infecciosas e Inmunología Pediátricas, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
Claudia MarcoDepartamento de Enfermedades Infecciosas e Inmunología Pediátricas, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
Jenniffer AnguloDepartamento de Enfermedades Infecciosas e Inmunología Pediátricas, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile; Laboratorio de Infectología y Virología Molecular, Red Salud UC-Christus, Santiago, Chile.
Aldo BarreraDepartamento de Enfermedades Infecciosas e Inmunología Pediátricas, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
Carlos PalmaLaboratorio de Infectología y Virología Molecular, Red Salud UC-Christus, Santiago, Chile.
Gonzalo Barriga PintoLaboratory of Emerging Viruses, Virology Program, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile, Santiago, Chile.
Analia CuizaPrograma Hantavirus y Zoonosis, Instituto de Ciencias e Innovación en Medicina, Facultad de Medicina Clínica Alemana Universidad del Desarrollo, Santiago, Chile.
Leonila FerreiraHospital Regional Guillermo Grant Benavente, Concepción, Chile.
María Luisa RiosecoHospital Regional de Puerto Montt, Universidad San Sebastián, Sede Patagonía, Puerto Montt, Chile.
Mario CalvoHospital Regional de Valdivia, Valdivia, Chile.
Ricardo FritzInstituto Nacional del Tórax, Santiago, Chile.
Sebastián BravoDepartamento de Medicina Intensiva, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
Alejandro BruhnDepartamento de Medicina Intensiva, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
Jerónimo GrafClínica Alemana de Santiago, Santiago, Chile.
Alvaro LlancaqueoHospital de las Higueras, Talcahuano, Chile.
Gonzalo RiveraHospital Hernán Henríquez Aravena, Temuco, Chile.
Carolina CerdaHospital Hernán Henríquez Aravena, Temuco, Chile.
Nicole TischlerFundación Ciencia & Vida, Universidad San Sebastián, Facultad de Medicina y Ciencia, Laboratorio de Virología Molecular, Santiago, Chile.
Francisca ValdiviesoUnidad Medicina del Viajero, Clinica Alemana de Santiago, Chile.
Pablo VialPrograma Hantavirus y Zoonosis, Instituto de Ciencias e Innovación en Medicina, Facultad de Medicina Clínica Alemana Universidad del Desarrollo, Santiago, Chile; Departamento de Pediatría, Clínica Alemana de Santiago, Chile.
Gregory MertzUniversity of New México, Albuquerque, NM, USA.
Cecilia VialPrograma Hantavirus y Zoonosis, Instituto de Ciencias e Innovación en Medicina, Facultad de Medicina Clínica Alemana Universidad del Desarrollo, Santiago, Chile.
Nicole Le CorreDepartamento de Enfermedades Infecciosas e Inmunología Pediátricas, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile; Laboratorio de Infectología y Virología Molecular, Red Salud UC-Christus, Santiago, Chile.
Pontificia Universidad Católica de Chile · CLClínica Alemana · CLHospital Doctor Hernán Henríquez Aravena · CLFundación Ciencia and Vida · CLHospital Las Higueras · CLHospital Regional de Concepción · CLInstituto Nacional del Tórax · CLSan Sebastián University · CLUniversity of Chile · CLUniversity of New Mexico · US

Funding

Andes virus transmission and pathogenesis in ChileU01AI045452 · NIAID · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI MERTZ, GREGORY JAMES · 2010 to 2014
$2.7M
'Fat'Nucleosides and NucleotidesR01AI055452 · NIAID · UNIVERSITY OF MARYLAND BALT CO CAMPUS · PI HOSMANE, RAMACHANDRA S · 2002 to 2005
$1.1M
NIAID NIH HHS R01 AI055452NIAID NIH HHS U01 AI045452
6 · The paper itself

Abstract

backgroundAndes virus (ANDV) is a zoonotic Orthohantavirus leading to hantavirus cardiopulmonary syndrome. Although most transmissions occur through environmental exposure to rodent faeces and urine, rare person-to-person transmission has been documented, mainly for close contacts. This study investigates the presence and infectivity of ANDV in body fluids from confirmed cases and the duration of viraemia.

methodsIn this prospective study, 131 participants with confirmed ANDV infection were enrolled in Chile in a prospective study between 2008 and 2022. Clinical samples (buffy coat, plasma, gingival crevicular fluid [GCF], saliva, nasopharyngeal swabs [NPS], and urine) were collected weekly for 3 weeks together with clinical and epidemiological data. Samples were categorised as acute or convalescent (up to and after 16 days following onset of symptoms). Infectivity of positive fluids was assessed after the culture of samples on Vero E6 cells and use of flow cytometry assays to determine the production of ANDV nucleoprotein.

findingsANDV RNA was detected in 100% of buffy coats during acute phase, declining to 95% by day 17, and to 93% between days 23-29. ANDV RNA in GCF and saliva decreased from 30% and 12%, respectively, during the acute phase, to 12% and 11% during the convalescent phase. Successful infectivity assays of RT-qPCR-positive fluids, including GCF, saliva, NPS, and urine, were observed in 18 (42%) of 43 samples obtained during the acute phase of infection. After re-culture, the capacity to infect Vero E6 cells was maintained in 16 (89%) of 18 samples. Severity was associated with the presence of ANDV RNA in one or more fluids besides blood (odds ratio 2·58 [95% CI 1·42-5·18]).

interpretationANDV infection is a systemic and viraemic infection, that affects various organs. The presence of infectious particles in body fluids contributes to our understanding of potential mechanisms for person-to-person transmission, supporting the development of preventive strategies. Detection of ANDV RNA in additional fluids at hospital admission is a predictor of disease severity.

fundingNational Institutes of Health and Agencia de Investigación y Desarrollo. TRANSLATION: For the Spanish translation of the abstract see Supplementary Materials section.

Indexed as

Hantavirus InfectionsOrthohantavirusViremiaVirus SheddingAdolescentAdultAgedAnimalsChildChileChlorocebus aethiopsFemaleHumansMaleMiddle AgedProspective StudiesRNA, Viral

Identifiers

PMID38582089
PMCPMC11193614
OpenAlexW4393858219

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.